The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Anticipated For The Rare Gastrointestinal Diseases Treatment Market Over The Period 2026–2030?
The rare gastrointestinal diseases treatment market size has shown substantial growth in recent years. It is anticipated to expand from $1.45 billion in 2025 to $1.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.9%. The expansion witnessed in the historical period can be ascribed to several factors, including heightened recognition of rare GI disorders, the proliferation of specialty gastroenterology centers, the accessibility of immunosuppressive and anti-inflammatory drugs, increasing clinical research activity, and improved diagnostic accuracy.
The market size for rare gastrointestinal diseases treatment is expected to experience significant expansion in the coming years. It is forecast to grow to $1.91 billion by 2030, driven by a compound annual growth rate (CAGR) of 5.6%. This growth during the forecast period is attributable to the increasing development of orphan drugs, rising investments in rare disease research, growing adoption of biologic therapies, the expansion of precision medicine approaches, and increasing patient access to advanced treatments. Furthermore, major trends anticipated in the forecast period include the increasing adoption of targeted biologic therapies, a rising focus on personalized treatment protocols, the growing use of advanced diagnostic devices, the expansion of enzyme replacement therapies, and enhanced integration of digital patient monitoring.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28317&type=smp
What Underlying Factors Are Accelerating The Growth Of The Rare Gastrointestinal Diseases Treatment Market?
The expansion of diagnostic testing is anticipated to boost the rare gastrointestinal diseases treatment market in the future. These medical tests are crucial for identifying, diagnosing, or overseeing diseases, conditions, or infections in individuals. The growing need for diagnostic tests stems mainly from increased understanding of the importance of detecting illnesses early, which facilitates prompt treatments and better patient results. For rare gastrointestinal diseases, diagnostic testing is instrumental in treatment by allowing for early and precise identification of underlying issues. It assists in pinpointing specific disease mechanisms, enabling customized treatment strategies, and enhancing patient outcomes through rapid intervention. As an illustration, data from December 2024 by the National Health Service, a UK government body, indicated that the volume of diagnostic tests performed reached 2,544,809 in 2024, representing an increase from 2,312,030 in 2023. Consequently, the uptick in diagnostic testing is fueling the expansion of the rare gastrointestinal diseases treatment market.
How Is The Rare Gastrointestinal Diseases Treatment Market Divided Into Its Major Segments?
The rare gastrointestinal diseases treatment market covered in this report is segmented –
1) By Type: Drugs, Device
2) By Route Of Administration: Oral, Intravenous (IV) Or Injectable, Subcutaneous, Other Routes Of Administration
3) By Application: Eosinophilic Gastroenteritis, Hercksprung’s Disease, Chronic Intestinal Pseudo-Obstruction
4) By End User: Hospitals, Research Institutes, Other End Users
Subsegments:
1) By Drugs: Anti-Inflammatory Drugs, Immunosuppressive Agents, Biologic Therapies, Antibiotics, Proton Pump Inhibitors, Corticosteroids, Enzyme Replacement Therapies
2) By Devices: Endoscopic Devices, Diagnostic Imaging Systems, Surgical Instruments, Feeding Tubes, Stent Devices, Biopsy Devices
How Are Trends Transforming The Rare Gastrointestinal Diseases Treatment Market Landscape?
Companies operating within the rare gastrointestinal diseases treatment market are concentrating on creating innovative therapies, such as fully human monoclonal antibodies, to target disease pathways and enhance patient outcomes. Fully human monoclonal antibodies are laboratory-engineered antibodies made entirely from human proteins, designed to specifically target disease-causing molecules. This approach helps to precisely block or modulate these molecules, improving treatment effectiveness while minimizing side effects. For example, in August 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, obtained U.S. Food and Drug Administration (FDA) approval for Veopoz (pozelimab-bbfg) for CHAPLE disease, an uncommon and life-threatening hereditary gastrointestinal disorder. Veopoz is a fully human monoclonal antibody formulated to target complement factor C5, assisting in the regulation of the overactive complement system that leads to protein loss and gastrointestinal damage in individuals with CHAPLE. This targeted mechanism of action addresses the underlying cause of the disease, thereby preventing debilitating symptoms and potentially fatal complications.
Who Are The Prominent Organizations Shaping The Rare Gastrointestinal Diseases Treatment Market?
Major companies operating in the rare gastrointestinal diseases treatment market are Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Bayer AG, Sanofi S.A., Zealand Pharma A/S, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Ipsen S.A., PTC Therapeutics Inc., Ironwood Pharmaceuticals Inc., Mirum Pharmaceuticals Inc., Albireo Pharma Inc., Orphalan S.A., Ellodi Pharmaceuticals Inc.
Read the full rare gastrointestinal diseases treatment market report here:
Which Region Is Projected To Dominate The Rare Gastrointestinal Diseases Treatment Market During The Forecast Period?
North America was the largest region in the rare gastrointestinal diseases treatment market in 2025. The regions covered in the rare gastrointestinal diseases treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Rare Gastrointestinal Diseases Treatment Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=28317&type=smp
Browse Through More Reports Similar to the Global Rare Gastrointestinal Diseases Treatment Market 2026, By The Business Research Company
Rare Diseases Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report
Rare Inflammatory Disease Treatment Market Report 2026
Gastrointestinal Drug Market Report 2026
https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model